In July 2022, PCP provided a SEK 350 million term loan to Avia Pharma AB, a Swedish pharmaceutical company focused on general OTC, Women’s Health, Urology and Dermatology. The term loan was used to partly finance Avia’s acquisitions of three pharmaceutical portfolios/companies in Sweden, Finland and Germany.
Avia Pharma was founded in 2015 and is a Swedish pharma company with sales and marketing organizations in all four Nordic countries executing a buy and build strategy. The founders/management have significant experience within the pharmaceutical industry, with the CEO and the COB being former employees/investors at Apoteket Hjärtat.
Avia sells pharmaceuticals both through its owned portfolio and license agreements with a well-diversified portfolio. Furthermore, the recent acquisition of the German company, Allergika GmbH, facilitates further expansion into the German market.
PCP appreciates the stability and growth of both the underlying pharmaceutical market and Avia’s pharmaceutical portfolio. We are also happy to support the growth of a Swedish entrepreneurial company backed by a strong founder team.